Abstract
We report the synthesis and relevant pharmacological properties of the quinoxalinetacrine (QT) hybrid QT78 in a project targeted to identify new non-hepatotoxic tacrine derivatives for Alzheimer’s disease therapy. We have found that QT78 is less toxic than tacrine at high concentrations (from 100 µM to 1 mM), less potent than tacrine as a ChE inhibitor, but shows selective BuChE inhibition (IC50 (hAChE) = 22.0 ± 1.3 µM; IC50 (hBuChE) = 6.79 ± 0.33 µM). Moreover, QT78 showed effective and strong neuroprotection against diverse toxic stimuli, such as rotenone plus oligomycin-A or okadaic acid, of biological significance for Alzheimer’s disease.
Original language | English |
---|---|
Article number | 1503 |
Journal | Molecules |
Volume | 24 |
Issue number | 8 |
DOIs | |
Publication status | Published - Apr 17 2019 |
Keywords
- Alzheimer’s disease
- Cholinesterase inhibitor
- Hepatotoxicity
- Molecular modeling
- Neuroprotection
- Quinoxalines
- Quinoxalinetacrines
- Tacrine
ASJC Scopus subject areas
- Analytical Chemistry
- Chemistry (miscellaneous)
- Molecular Medicine
- Pharmaceutical Science
- Drug Discovery
- Physical and Theoretical Chemistry
- Organic Chemistry